(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.

BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently ...

BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from ...

BioAge Labs, Inc BIOA IPO will take place September, 26 on the NASDAQ exchange under the ticker BIOA. The company is offering shares at an expected price between $17.00 and $19.00 per share with an ...

The Dallas-based company focuses on so-called outparcels, properties that point directly onto high-traffic roads that are visible to consumers, and Illinois is its largest market.

Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.

"IG index spreads narrowed 0-1bp during yesterday’s session, and the ICE Corporate index opens this morning at a spread to Treasuries of 92bp. That’s the narrowest spread for the IG index since July ...

Plus, news about BioAge, Fulcrum Therapeutics and Arcutis Biotherapeutics: Sanofi snags Greater China rights to CD73 antibody: The French pharma will pay TJ Biopharma €32 million (or about $35 million ...

September 25, 2024 • Shady Rest Country Club in Scotch Plains, N.J., was established in 1921. The sports and entertainment venue is being renovated, with help from a special historic ...